Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
ABCDE: A Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Indiana Unversity Simon Cancer Center
mi
from
Indianapolis, IN
Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
ABCDE: A Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana Unversity Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
ABCDE: A Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of North Carolina Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
ABCDE: A Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of North Carolina Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer II)
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer Study II)
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer II)
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer Study II)
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer II)
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer Study II)
Status: Enrolling
Updated:  12/31/1969
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer II)
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer Study II)
Status: Enrolling
Updated: 12/31/1969
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer II)
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer Study II)
Status: Enrolling
Updated:  12/31/1969
University of Illinois
mi
from
Champaign, IL
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer II)
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer Study II)
Status: Enrolling
Updated: 12/31/1969
University of Illinois
mi
from
Champaign, IL
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
John Hopkins Medical Center
mi
from
Baltimore, MD
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
John Hopkins Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of North Carolina School of Medicine
mi
from
Chapel Hill, NC
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of North Carolina School of Medicine
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Georgetown University
mi
from
Washington,
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Washington Cancer Institute at Washington
mi
from
Washington,
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Washington Cancer Institute at Washington
mi
from
Washington,
Click here to add this to my saved trials
Single Dose Partial Breast Radiotherapy
Single Dose Partial Breast Radiotherapy Using Extra-cranial Radiosurgery in Patients With Early Stage Breast Cancer - a Phase I Dose Escalation Study
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Single Dose Partial Breast Radiotherapy
Single Dose Partial Breast Radiotherapy Using Extra-cranial Radiosurgery in Patients With Early Stage Breast Cancer - a Phase I Dose Escalation Study
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Recurrent Breast Cancer
Partial Breast Re-Irradiation for Patients With Ipsilateral Breast Tumor Recurrence, After First Being Treated With Breast Conservation for Early Stage Breast Cancer: An Efficacy Trial Comparing Mammosite® and Intraoperative Radiation
Status: Enrolling
Updated:  12/31/1969
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Radiation Therapy in Treating Patients With Recurrent Breast Cancer
Partial Breast Re-Irradiation for Patients With Ipsilateral Breast Tumor Recurrence, After First Being Treated With Breast Conservation for Early Stage Breast Cancer: An Efficacy Trial Comparing Mammosite® and Intraoperative Radiation
Status: Enrolling
Updated: 12/31/1969
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Recurrent Breast Cancer
Partial Breast Re-Irradiation for Patients With Ipsilateral Breast Tumor Recurrence, After First Being Treated With Breast Conservation for Early Stage Breast Cancer: An Efficacy Trial Comparing Mammosite® and Intraoperative Radiation
Status: Enrolling
Updated:  12/31/1969
UHHS Westlake Medical Center
mi
from
Cleveland, OH
Radiation Therapy in Treating Patients With Recurrent Breast Cancer
Partial Breast Re-Irradiation for Patients With Ipsilateral Breast Tumor Recurrence, After First Being Treated With Breast Conservation for Early Stage Breast Cancer: An Efficacy Trial Comparing Mammosite® and Intraoperative Radiation
Status: Enrolling
Updated: 12/31/1969
UHHS Westlake Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Recurrent Breast Cancer
Partial Breast Re-Irradiation for Patients With Ipsilateral Breast Tumor Recurrence, After First Being Treated With Breast Conservation for Early Stage Breast Cancer: An Efficacy Trial Comparing Mammosite® and Intraoperative Radiation
Status: Enrolling
Updated:  12/31/1969
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Radiation Therapy in Treating Patients With Recurrent Breast Cancer
Partial Breast Re-Irradiation for Patients With Ipsilateral Breast Tumor Recurrence, After First Being Treated With Breast Conservation for Early Stage Breast Cancer: An Efficacy Trial Comparing Mammosite® and Intraoperative Radiation
Status: Enrolling
Updated: 12/31/1969
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases
Status: Enrolling
Updated:  12/31/1969
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases
Status: Enrolling
Updated: 12/31/1969
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases
Status: Enrolling
Updated:  12/31/1969
University Hospitals Chagrin Highlands Medical Center
mi
from
Orange Village, OH
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases
Status: Enrolling
Updated: 12/31/1969
University Hospitals Chagrin Highlands Medical Center
mi
from
Orange Village, OH
Click here to add this to my saved trials
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases
Status: Enrolling
Updated:  12/31/1969
University Hospitals-Westlake
mi
from
Westlake, OH
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases
Status: Enrolling
Updated: 12/31/1969
University Hospitals-Westlake
mi
from
Westlake, OH
Click here to add this to my saved trials
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases
Status: Enrolling
Updated:  12/31/1969
University Hospitals Monarch
mi
from
Mayfield Heights, OH
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases
Status: Enrolling
Updated: 12/31/1969
University Hospitals Monarch
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Chandler, AZ
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Chandler, AZ
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Flagstaff, AZ
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Flagstaff, AZ
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Gilbert, AZ
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mesa, AZ
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mesa, AZ
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Sedona, AZ
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Sedona, AZ
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Tucson, AZ
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Bakersfield, CA
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Beverly Hills, CA
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Fullerton, CA
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
La Jolla, CA
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
La Jolla, CA
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Long Beach, CA
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Pablo, CA
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Pablo, CA
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Santa Maria, CA
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Hollywood, FL
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Hudson, FL
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Hudson, FL
Click here to add this to my saved trials